T. Rowe Price Investment Management Inc. Raises Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

T. Rowe Price Investment Management Inc. raised its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 39.7% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 4,384,449 shares of the biopharmaceutical company's stock after purchasing an additional 1,245,195 shares during the period. T. Rowe Price Investment Management Inc. owned approximately 3.40% of Alnylam Pharmaceuticals worth $1,031,705,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Capital World Investors increased its position in shares of Alnylam Pharmaceuticals by 0.6% during the fourth quarter. Capital World Investors now owns 16,600,525 shares of the biopharmaceutical company's stock valued at $3,906,284,000 after acquiring an additional 92,101 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Alnylam Pharmaceuticals by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 12,733,399 shares of the biopharmaceutical company's stock worth $2,996,296,000 after acquiring an additional 98,303 shares in the last quarter. Capital Research Global Investors boosted its stake in Alnylam Pharmaceuticals by 32.9% in the 4th quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock worth $1,639,767,000 after purchasing an additional 1,724,610 shares during the period. Regeneron Pharmaceuticals Inc. purchased a new position in Alnylam Pharmaceuticals during the fourth quarter valued at approximately $1,045,822,000. Finally, Norges Bank bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth $577,941,000. Institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY traded up $2.55 on Monday, reaching $254.11. The company's stock had a trading volume of 142,479 shares, compared to its average volume of 876,369. Alnylam Pharmaceuticals, Inc. has a 12-month low of $143.50 and a 12-month high of $304.39. The stock has a market capitalization of $33.06 billion, a P/E ratio of -116.91 and a beta of 0.30. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The stock's 50 day simple moving average is $247.37 and its two-hundred day simple moving average is $255.84.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). Research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Jeffrey V. Poulton sold 967 shares of the firm's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $246,749.39. Following the sale, the chief financial officer now directly owns 32,786 shares in the company, valued at $8,366,003.62. This trade represents a 2.86 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the company's stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.21, for a total value of $169,204.23. Following the completion of the transaction, the executive vice president now directly owns 14,321 shares of the company's stock, valued at approximately $3,654,862.41. This trade represents a 4.42 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 7,392 shares of company stock worth $1,875,627 over the last quarter. 1.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on ALNY. HC Wainwright reaffirmed a "buy" rating and issued a $500.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 2nd. Stifel Nicolaus upped their target price on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a "buy" rating in a report on Monday, March 31st. Canaccord Genuity Group increased their price target on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a "buy" rating in a research note on Friday, March 21st. Needham & Company LLC reissued a "buy" rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 9th. Finally, Redburn Atlantic initiated coverage on Alnylam Pharmaceuticals in a research note on Monday, March 31st. They issued a "buy" rating and a $353.00 price target on the stock. One research analyst has rated the stock with a sell rating, four have given a hold rating and twenty-two have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $315.58.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.